Dextrifer

Quick links to important sections

Dextrifer

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dextrifer

Property Description
Active Ingredient Ferric Hydroxide (Trivalent Iron)
Form Oral Solution, Drops, Syrup, Chewable Tablets; Intravenous Solution
Pharmacological Class Antianemic Agent (Hematinic)
Common Use Iron supplementation and replacement
Origin Synthetic Compound (Inorganic Iron Salt Complex)

What Type of Medicine is Dextrifer? (Identity and Classification)

Dextrifer is a specialized Antianemic Agent that functions as an Iron Preparation belonging to the high-level pharmacological class of Hematinics. This classification establishes the medicine's role in supporting blood health and iron balance. The active ingredient, Ferric Hydroxide, corresponds to the Iron Trivalent Oral Preparation grouping. This formulation is recognized in clinical practice for its application in replacing the body’s essential iron stores, a necessity often encountered during periods of increased demand or chronic loss. Formulations containing Ferric Hydroxide are commonly utilized for oral supplementation due to their favorable absorption characteristics.


Composition and Forms: Trivalent Iron and Differentiating Features

The active component in Dextrifer is Ferric Hydroxide (Iron (III) Hydroxide), a compound delivering Trivalent Iron which is typically stabilized within a complex, such as the Ferric Hydroxide Polymaltose Complex. This synthetic complex differentiates it from simpler iron salts, offering an alternative that may be better tolerated. Dextrifer is notably distinguished by its versatile range of dosage forms primarily for Oral administration, including chewable tablets, syrup, drops, and oral solutions, positioning it for use across different patient groups. For clinical needs requiring immediate iron repletion, a separate, specialized Intravenous solution for injection (DEXTRIFER-S) is also produced for administration under medical supervision.


The General Purpose of Ferric Hydroxide in the Body

The fundamental purpose of Dextrifer is to restore the body’s essential iron stores, thereby addressing the underlying mineral deficit required for health. Iron is an indispensable mineral utilized to synthesize hemoglobin, the protein crucial for transporting oxygen from the lungs throughout the entire body. By providing a readily bioavailable source of Trivalent Iron, this preparation directly supports the physiological processes necessary to sustain optimal oxygen transport, an action recognized as vital for maintaining energy levels and tissue function.

What side effects are possible with Dextrifer?

Possible side effects and safety information

The safety profile for Dextrifer, based on its active ingredient Ferric Hydroxide (Trivalent Iron) complex, is characterized by adverse reactions primarily affecting the gastrointestinal system, as classified in official regulatory documents. Safety classifications are based on observed frequencies from clinical trials and post-marketing surveillance.


Documented Adverse Reactions by Frequency

Frequency Classification Examples of Reactions (System Organ Class)
Very Common (ge 1/10) Faeces discoloration (Dark stools) (Gastrointestinal)
Common (ge 1/100 to < 1/10) Nausea, Diarrhoea, Constipation, Abdominal pain (Gastrointestinal)
Uncommon (ge 1/1000 to < 1/100) Vomiting, Gastritis, Headache, Pruritus, Rash, Tooth discoloration (Gastrointestinal, Nervous System, Skin)

Faeces discoloration is the most frequently reported effect of oral iron and is generally considered to be of no clinical relevance, as noted by regulatory authorities. Reactions occurring with uncommon frequency also extend to Skin and Subcutaneous Tissue Disorders (e.g., pruritus and rash).


Serious Reactions and Safety Constraints

Serious Adverse Reactions are rare; however, post-marketing reports document Very Rare incidence of Hypersensitivity/Allergic Reactions, including systemic reactions and asthma. The medicine is contraindicated in conditions involving iron overload (e.g., hemochromatosis) or anaemia not caused by iron deficiency (e.g., haemolytic anaemia). A high-level safety note states that the concomitant administration of parenteral iron and the oral complex is not recommended.


Population-Specific Notes

Regulatory documents emphasize that accidental overdose of iron-containing products can cause fatal toxicity in children below 6 years of age, necessitating the product be kept out of their sight and reach. Use during pregnancy or lactation should only occur after professional consultation.

Overdose and Emergency Response

Dextrifer Overdose and When to Seek Help

Dextrifer is a complex of iron and dextran, and an overdose involves receiving an excessively high amount of iron in the body. Since iron is not easily eliminated, an acute overdose can lead to serious toxicity, potentially resulting in multi-system failure. Because Dextrifer is administered by a healthcare professional, overdose is rare, but all patients should be aware of the signs of acute iron poisoning.

Symptoms of Acute Iron Poisoning

Symptoms of an acute iron overdose may progress in phases. Initial signs can include severe gastrointestinal effects like nausea, vomiting (potentially with blood), abdominal pain, and diarrhea. In severe poisoning, systemic toxicity may occur, characterized by:

  • Cardiovascular: Low blood pressure (hypotension) and shock, rapid or weak pulse.
  • Nervous System: Dizziness, drowsiness, seizures, and eventual coma.
  • Metabolic: Severe metabolic acidosis.

Following the initial symptoms, there may be a deceptive period where symptoms improve, but this can be followed by a recurrence of severe symptoms, including liver damage and potential death. Long-term effects, such as scarring and blockage of the gastrointestinal tract, may occur weeks later.

When to Seek Emergency Help

If you believe you have received too much Dextrifer, or if you develop any of the following severe symptoms, you must seek emergency medical attention immediately:

  • Uncontrollable vomiting or vomiting blood
  • Severe abdominal pain
  • Loss of consciousness or seizures
  • Blue-tinged lips or fingernails
  • Rapid or weak pulse and dizziness when standing

The treatment for a significant iron overdose often involves supportive care and the use of an iron-chelating agent, such as deferoxamine, to help remove excess iron from the body.

Therapeutic Uses of Dextrifer

What Dextrifer Treats: Main Uses and Benefits

The key purpose of Dextrifer is to provide short-term, supportive relief across several symptomatic domains, assisting with managing acute discomfort and supporting a sense of stability during challenging episodes. The medication is commonly used to temporarily ease symptomatic burden caused by various conditions.


Therapeutic Focus: Symptom Clusters and Functional Support

Dextrifer is generally used in clinical settings that involve acute or unstable symptom patterns, such as those associated with episodic manifestations, symptoms related to physical discomfort, or systemic imbalance. It may assist with managing symptom clusters that may become intense or disruptive and can be applied in scenarios where additional management of discomfort is required. The primary therapeutic focus is on providing supportive relief for acute symptom fluctuation, heightened discomfort, and temporary functional strain.

“The goal of Dextrifer is to provide supportive relief, helping patients cope more steadily with symptom fluctuations.”


Key Benefits

Dextrifer provides support that helps ease the overall symptom burden, contributes to easing discomfort during periods of heightened symptoms, and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Supportive Relief for Acute Symptomatic Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Population Eligibility Rules

Dextrifer's eligibility profile is strictly defined by regulatory documents, limiting its use to patients with documented iron deficiency. It is approved for use in adults, older adults, and children, though liquid forms are typically established for younger age groups.

Absolute Non-Eligibility (Contraindications)

The medicine is strictly contraindicated for several populations. Individuals must not use Dextrifer if they have an anemia not caused by iron deficiency (such as Haemolytic or Megaloblastic anemia). It is also prohibited for patients with iron overload syndromes (e.g., Haemochromatosis) or a known hypersensitivity to any component. Furthermore, use is generally contraindicated in cases of severe liver or kidney diseases.

Restricted and Conditional Use

Use is not recommended for children under 12 years of age when using the tablet formulation, due to insufficient data for that specific dosage form. For pregnancy and lactation, use is generally permissible—including after the first trimester—but it requires consultation and supervision by a medical professional. Caution is also advised for patients with active gastrointestinal organic conditions.

What should I know about interactions with other medicines?

Dextrifer's interaction profile is structured around pharmacokinetic interactions that significantly reduce the systemic exposure of several co-administered medicinal products, necessitating specific administration rules documented in official regulatory prescribing information.

Interactions Requiring Administration Separation:

Interacting Substance/Class Official Interaction Outcome Timing Requirement
Antivirals (e.g., Dolutegravir) Decreased systemic exposure of the antiviral agent. Administer the antiviral at least 2 hours before or 6 hours after oral iron.
Thyroid Preparations (e.g., Levothyroxine) Reduced absorption and decreased serum concentration of the thyroid drug. Separate oral administration by at least 4 hours.
Bisphosphonates, Quinolones Reduced absorption and potential loss of efficacy of the co-administered drug. Requires dose separation (typically 2 to 4 hours).

Contraindications and Restrictions:

Co-administration with Dimercaprol is formally prohibited due to the potential for enhanced nephrotoxic effects of iron preparations, representing a pharmacodynamic interaction. A mandatory route restriction is enforced: the Intravenous form of Dextrifer must not be co-administered with any Oral Iron Preparations, requiring a delay of at least one week before starting oral therapy. Finally, regulatory documents specifically note that the absorption of Dextrifer is not impaired by meals or food components, a unique characteristic compared to simple iron salts.

Mechanism of Action

Dextrifer's active metabolite selectively accumulates in bone tissue and is internalized by active osteoclasts. Within the cell, Dextrifer acts as a specific, competitive inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS) in the mevalonate pathway. By occupying the active site, it blocks the synthesis of essential isoprenoid lipids, specifically geranylgeranyl diphosphate (GGPP). This depletion of GGPP prevents the necessary prenylation and functional activation of small GTPase signaling proteins, such as Rho and Rac. The resulting dysfunction in GTPase signaling disrupts the cytoskeletal structure and the formation of the osteoclast ruffled border, which are critical for bone resorption activity. This intracellular cascade ultimately leads to the induction of osteoclast apoptosis (programmed cell death), thereby reducing bone resorption at the cellular level.

Dosage and Administration Information

How to Use Dextrifer

Dextrifer, an iron preparation utilizing Ferric Hydroxide Polymaltose Complex, is administered according to a defined protocol focused on restoring the body's iron stores and normalizing hemoglobin levels. All usage patterns are defined according to established clinical protocols.


Administration Guidelines

Usage Entity Map (High-Level) Instruction
Route of Administration The standard and primary route for all dosage forms (tablets, capsules, solutions) is Oral.
Standard Adult Dosing The typical range for treating iron deficiency anemia is 100 mg to 200 mg of elemental iron daily. Doses up to 300 mg daily may be used for severe deficiency.
Timing and Frequency The total daily dose may be taken as a single dose or in divided doses. Administration must occur during or immediately after a meal to fulfill administration timing requirements.
Preparation Details The oral drops and syrups can be mixed with fruit juice or infant formula, as this does not compromise the product's efficacy. Chewable tablets may be chewed or swallowed whole.
Pediatric Rules Dosing for infants and children is determined precisely by age and body weight, such as drops per kilogram, and is not a generalized adult dose.
Special Conditions The simultaneous use of oral and parenteral iron preparations is avoided. A dark colouration of the stool is an expected, clinically insignificant finding of the treatment course.

Course Duration Protocol

The treatment course is structured in two parts. The initial phase continues until the hemoglobin value has been successfully normalized. This is followed by a replenishment phase, which requires continuation of the daily administration for a minimum of one additional month to ensure the body's iron stores are fully restored. Adherence to this defined timeline and the timing with meals constitutes the fundamental procedural framework for proper use.

Recent Clinical Evidence

Evidence for Use in Iron Deficiency Anemia (IDA) and Iron Deficiency (ID)

The core research on Dextrifer (Ferric Hydroxide Polymaltose Complex) has primarily examined its role in addressing Iron Deficiency Anemia (IDA) and simple Iron Deficiency (ID). Randomized Controlled Trials (RCTs) and systematic reviews were studied for their potential to examine the compound's effect on iron stores. Research consistently monitored Hemoglobin (Hb) concentration and the body's iron storage levels (Serum Ferritin) as the key outcomes studied in general adult populations.


Comparing Dextrifer to Other Iron Supplements in Clinical Trials

Dextrifer was evaluated in trials designed to understand its characteristics relative to traditional oral iron options, particularly ferrous salts. The findings describe patterns observed where Dextrifer was studied for its potential to provide changes in Hemoglobin levels similar to those observed with older iron salts. However, when looking at the more complex marker of stored iron (Serum Ferritin), findings were mixed across various studies, indicating that the measurements may differ from those observed with older comparators.


Evidence in Special Populations: Pregnancy and Children

Research has specifically studied the use of Dextrifer in pregnant women, a group often studied due to naturally high iron demands. Dextrifer was evaluated in pediatric groups for both treating established iron deficiency and for prevention (prophylaxis) in high-risk scenarios. Findings were mixed when comparing results to ferrous salts in children, with some research data showing patterns where the observed increases in ferritin levels differed. This subgroup finding is uncertain.


Long-Term Studies and Follow-up Data

Most available research studies explored treatment responses over short-term to intermediate intervals, typically lasting around three to four months. Follow-up durations were limited, and long-term effects are not fully established regarding the durability of iron store repletion. This means the existing research provides limited insight into how iron levels may change after the study participants completed the defined treatment interval. Furthermore, the evidence relies heavily on laboratory blood values rather than long-term outcomes reflecting daily functioning.

Key Studies & References

  1. Iron (III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia (A meta-analysis comparing IPC with ferrous sulfate)
  2. Comparison of efficacy and tolerability of iron polymaltose complex with ferrous sulphate in treatment of children with iron deficiency anemia

Frequently Asked Questions (FAQ)

Common questions about Dextrifer (FAQ)

Q: How quickly should I expect to feel the effects of Dextrifer?

Official information indicates that iron replacement therapy is a gradual process. While clinical measures like hemoglobin are expected to begin rising within 2 to 4 weeks, individual physical symptoms, such as fatigue, may take a similar or slightly longer timeframe to show improvement. The treatment aims for a steady restoration of the body's iron stores.

Q: Can Dextrifer be taken long-term for chronic conditions?

Regulatory documents note that the full course of treatment extends beyond the time needed to normalize hemoglobin; it includes a replenishment phase of at least one additional month to fully restore iron stores. Longer-term use may be considered for chronic deficiencies, with the final duration determined by a healthcare provider.

Q: Does Dextrifer interact with caffeine or alcohol?

While the official prescribing information primarily focuses on drug-drug interactions, general caution is often advised for iron products when alcoholism is a factor, as this condition can affect iron absorption. Dextrifer is generally noted to have reduced interactions with food and beverages. Patients should review their specific product label for any warnings, including those regarding caffeine.

Q: What happens if I stop taking Dextrifer suddenly?

Stopping the medication abruptly before the prescribed course is complete may result in the incomplete correction of the iron deficiency or anemia. Treatment is designed to not only normalize blood levels but also to refill long-term iron stores. Premature cessation may lead to a relapse of deficiency symptoms.

Q: Is Dextrifer available over the counter, or is it prescription-only?

The regulatory status of iron supplements, including those containing Ferric Hydroxide Polymaltose Complex, can vary significantly depending on the country and the strength of the product. In some jurisdictions, it is available by prescription only, while in others, it may be available over the counter.

Q: What's the difference between Dextrifer and [Similar Drug Name]?

Dextrifer contains a specific form of iron called Iron(III) Hydroxide Polymaltose Complex (IPC). Clinical reviews suggest that this complex-bound iron may be better tolerated and can cause fewer gastrointestinal side effects compared to older, simple iron salts. This difference is often noted as a reason for its use in certain patient groups.

Q: Can older adults safely take Dextrifer?

Dextrifer is typically approved for use in older adults. They usually receive the standard adult dosage, but dosing may be determined by a healthcare provider based on an individual's overall health and concurrent medications.

Q: Are there known interactions between Dextrifer and herbal supplements?

Official prescribing documents list interactions with specific classes of prescription and over-the-counter drugs but generally do not include an exhaustive list of herbal supplements. Patients are generally advised to inform a healthcare professional about all supplements being taken.

Q: Does Dextrifer cause weight gain or loss?

Weight change is typically not listed as a common or uncommon side effect in the regulatory safety documentation for Dextrifer. The most frequently documented side effects are related to the digestive system, such as nausea and constipation.

Q: Can Dextrifer be taken with food, or is it better on an empty stomach?

Official instructions recommend taking Dextrifer during or immediately after a meal. This is often to help minimize any potential for stomach upset. Unlike older iron salts, the absorption of Dextrifer's complex-bound iron is generally not impaired by food.

Q: Is it possible to be allergic to Dextrifer?

Yes, it is possible. Official safety information states that Dextrifer is contraindicated (prohibited) for anyone with a known hypersensitivity to the active substance or any of its components. Allergic reactions are documented as a very rare potential adverse effect.

Q: How long does Dextrifer stay in your system after the last dose?

Iron is an essential mineral that the body actively utilizes. After absorption, the iron is either transported in the blood or stored in the body as ferritin. Unabsorbed iron is simply excreted. The body tightly regulates its iron stores, which are not rapidly eliminated after treatment ends.

Q: What should I do if I miss a dose of Dextrifer?

Official guidance often instructs that if a dose is missed, patients should follow the specific protocol defined in the Patient Information Leaflet (PIL). Typically, this involves either taking the dose as soon as remembered or skipping it if the next scheduled dose is close, avoiding doubling the dose.

Q: Do children ever take Dextrifer, and for what conditions?

Yes, Dextrifer, often in the form of drops, solutions, or syrups, is approved for use in children. It is used to both treat and prevent various forms of iron deficiency and iron deficiency anemia. The dosage is carefully calculated based on the child's age and body weight.

Q: Why is Dextrifer sometimes prescribed instead of other treatments?

Clinical reviews indicate that Dextrifer is often chosen as an alternative for patients who have difficulty tolerating or adhering to other oral iron preparations, particularly older iron salts. The reduced incidence of gastrointestinal side effects is a key reason for its use.

Q: What is the average duration of a Dextrifer treatment course?

The total duration of treatment is based on the severity of the deficiency. For iron deficiency with anemia, the treatment phase usually lasts an average of 3 to 5 months to normalize hemoglobin. This is always followed by the replenishment phase to refill the iron stores.

Q: Is it okay to crush or split Dextrifer tablets?

For chewable tablets, the official instructions confirm they can be chewed or swallowed whole. For other tablet forms, patients should follow the specific instructions provided on the product labeling for the tablets they are using. Liquid forms (drops/syrups) can often be mixed with fruit juice or infant formula.

Q: How is the effectiveness of Dextrifer measured in clinical trials?

The effectiveness of Dextrifer in clinical settings is measured through standard laboratory tests. The primary outcomes assessed are the levels of Hemoglobin (the oxygen-carrying protein in the blood) and Serum Ferritin (the protein that stores iron in the body).

How should Dextrifer be stored and disposed of?

How to Store and Dispose of Dextrifer?

The storage and disposal of Dextrifer (Iron Dextran Injection) must follow official regulatory labeling to ensure product integrity and safety.

Storage Requirements

The product must be stored at a temperature below 25°C and must not be frozen. It is mandatory to store the medicine out of the sight and reach of children. The ampoule is for single use only. Before use, the solution must be visually inspected, and only product that is clear and sediment-free should be administered. If diluted, the chemical and physical stability is limited to 24 hours at 25°C, or a maximum of 24 hours under refrigeration (2 C to 8 C) from a microbiological viewpoint.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of in accordance with local requirements. The medicine must not be disposed of in drains or household waste and should be returned to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dextrifer found in:

A-Z Index: